FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
By Research Team at The Peptide Source
An ARA 290 specification review should begin with the batch record, not a product name or a purity badge. ARA 290 is commonly described in research literature as an 11-residue, erythropoietin-derived peptide, often referred to as cibinetide. For a laboratory buyer, the relevant question is whether the material in a specific vial can be traced to a defined identity, documented purity result, and controlled release process.
Catalog-level claims are not equivalent to batch-level evidence. A usable research specification identifies what was tested, how it was tested, and which lot the data represent. That distinction matters when comparing research-grade peptide suppliers, especially where product labels and technical descriptions may otherwise look similar.
> Compliance Notice
>
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. ARA 290 materials discussed here are intended solely for legitimate laboratory, analytical, and preclinical research applications. They are not approved for human or veterinary use. No dosing, administration, or personal-use information is provided.
What an ARA 290 specification should establish
A specification is a defined acceptance standard, not marketing copy. For ARA 290, it should establish chemical identity, assay or purity, presentation, traceability, and handling controls. Each point should be supported by a batch-specific certificate of analysis, commonly called a COA.
The supplier should clearly identify the analyte as ARA 290 and state the peptide sequence in an unambiguous format. This is particularly relevant because N-terminal pyroglutamate is a structural feature frequently associated with the material described in the literature. A sequence line should indicate any terminal modification explicitly rather than leaving it implied by a trade name.
The reported molecular weight is another basic identity checkpoint. ARA 290 is generally reported with a molecular weight near 1,257.45 Da. Buyers should verify whether a specification reports average molecular weight or monoisotopic mass and whether the stated value corresponds to the declared salt form, solvate status, or other presentation details. A number without method context is useful only as a preliminary screen.
Identity testing: what to look for
A credible COA should identify the analytical method used to support identity. LC-MS is commonly used to confirm a peptide mass consistent with the expected analyte. HPLC retention time can support consistency against a reference material, but retention time alone does not establish sequence-level identity.
For higher-confidence workflows, request or retain documentation showing the expected mass, observed mass, instrument method, and acceptance criteria. Where a supplier references third-party testing, the report should identify the laboratory or testing entity, the sample or lot number, the date of analysis, and the result. A generic sample report is not a substitute for the current lot record.
ARA 290 purity specifications need method context
Purity claims are frequently presented as a single percentage, often greater than 99% by HPLC. That can be a meaningful release metric, but only if the underlying chromatogram and method details are available. HPLC area percent is not automatically a mass-balance assay, nor does it identify every impurity by structure.
A useful ARA 290 specification review asks whether the COA provides the chromatogram, detection wavelength, column chemistry, mobile-phase conditions or method identifier, integration approach, and stated purity result. The goal is not to demand unnecessary proprietary process detail. It is to determine whether the reported result can be connected to an actual analytical procedure and a defined lot.
Purity also has practical limits as a comparison tool. Two suppliers may each state 99% purity while using different HPLC methods, reporting conventions, or integration thresholds. A lot with a lower stated result is not automatically unsuitable, and a lot with a higher stated result is not automatically better. The documentation quality and identity evidence determine how much confidence the number deserves.
Research context and mechanism literature
ARA 290 has been evaluated in published experimental work as a short peptide derived from the helix B region of erythropoietin. Researchers have investigated signaling hypotheses involving the innate repair receptor model, often described as an erythropoietin receptor and CD131-containing receptor complex. This receptor assignment and downstream signaling interpretation should be treated as research context, not as a product-performance claim.
Experimental literature has examined cell-signaling responses, inflammatory mediator patterns, and tissue-model endpoints in vitro and in animal systems. Reported pathways in laboratory models include JAK2-associated signaling, PI3K/Akt-related signaling, and NF-kB-linked transcriptional activity. Results depend on model design, peptide concentration, timing, species, endpoint selection, and the identity controls used in each experiment.
A frequently cited foundational paper on nonerythropoietic erythropoietin-derived peptides is Brines et al., Proceedings of the National Academy of Sciences, 2008, DOI: 10.1073/pnas.0805592105. Earlier receptor-complex work from Brines and colleagues is often cited in this research area: DOI: 10.1073/pnas.0406491101. These references provide scientific context only. They do not validate a commercial lot, establish equivalence between materials, or support human use.
Literature is not a substitute for lot verification
Published studies may use material prepared under conditions that differ from commercial research-peptide supply. Differences can include synthesis route, purification method, counterion, storage history, and analytical confirmation. For that reason, literature review and vendor qualification are separate tasks.
A research team should not infer that a vial matches published material based solely on its name. The analytical package, chain of custody, and lot-specific COA are the relevant evidence for the vial under review.
Documentation and release controls
The strongest supplier documentation package connects each unit to a batch number and each batch number to a COA. At minimum, confirm that the vial label, outer packaging, invoice, and COA use matching lot identification. If those records cannot be reconciled, the material is difficult to place into a controlled research workflow.
Review whether the COA includes identity, HPLC purity, lot number, date, and release authorization. Additional useful fields include net peptide content, appearance, residual solvent testing where applicable, water content, bioburden or endotoxin information when specifically relevant to the planned laboratory workflow, and storage conditions. Not every assay applies to every research use, but an omission should be deliberate and understood.
Controlled-facility production and third-party verification can add confidence when supported by documents. They should not be treated as standalone claims. Ask whether the manufacturer COA and independent verification refer to the same batch, whether the material was sampled before or after packaging, and whether the testing scope covers identity as well as purity.
Packaging, storage, and handling review
Packaging should protect the material from avoidable environmental exposure and preserve lot traceability. A properly labeled vial should state the compound name, nominal content, lot number, and research-use restriction. Shipping documentation should maintain the same identifiers.
Storage instructions should come from the supplier's lot documentation and be integrated into the laboratory's own material-handling SOP. Do not assume that every lyophilized peptide has identical stability characteristics. Once a vial is opened or material is prepared for an assay, the laboratory should document preparation conditions, storage interval, and any repeat freeze-thaw exposure according to its established procedures.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. No article, COA, chromatogram, or published paper converts research material into a product for human or veterinary administration.
Decision standard for research buyers
A defensible ARA 290 purchase decision is based on evidence that can be retained with the study file. The preferred material is not merely described as high purity. It has a supplier-declared sequence, molecular-weight expectation, lot-matched LC-MS and HPLC evidence, traceable packaging, and a COA available for review before the material enters an experiment.
If a supplier cannot provide those basics, the practical cost is not only uncertainty about the vial. It is weaker experimental documentation later. For research teams that value repeatability, a specification review is best treated as part of assay preparation, not as an administrative step after purchase.